ESR1 and metastatic neoplasm: In addition, patients who had relapsed metastatic disease were more likely to have detectable cfDNA ESR1 mutations (p-value = 0.016 for ESR1), compared to patients who presented with de novo metastatic breast cancer (Table 2).